Application of polygonatum odoratum extract in preparation of medicine for improving type 2 diabetes

The regulating intestinal flora and serum metabolism by pyrubin methanol extract, solving the side effects of type 2 diabetes treatment drugs and insulin sensitivity problems, significantly improving blood sugar, weight and inflammation levels, restoring metabolites balance, and improving insulin sensitivity.

CN118924841APending Publication Date: 2024-11-12ZHEJIANG SHUREN UNIV +2
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410470614.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-04-18
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing type 2 diabetes treatments may cause side effects such as nausea, vomiting, flatulence, diarrhea and hypoglycemia, and are difficult to effectively improve insulin sensitivity and glycolipid metabolism.

Method used

Using pyrubin methanol extract, through the synergistic effect of intestinal microbiota and serum metabolism, the relative abundance of Alistipes, Odoribacter, Rikenella, Blautia and Ruminococcus is regulated, serum metabolite abnormalities are restored, and insulin sensitivity and glycolipid metabolism are improved.

Benefits of technology

It significantly improves the blood sugar, weight, blood lipids and inflammation levels of mice, corrects intestinal microecology disorders, restores metabolite levels, improves insulin sensitivity, reduces inflammation, and has anti-inflammatory effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924841A_ABST
    Figure CN118924841A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological pharmacy, in particular to application of a polygonatum odoratum extract in preparation of a medicine for improving type 2 diabetes mellitus, and the polygonatum odoratum extract improves the type 2 diabetes mellitus through the synergistic effect of intestinal microbiota and serum metabolism. The research result shows that the polygonatum odoratum extract can interfere with the development of T2DM on multiple biological levels, so that the living quality of a patient is improved, and the risk of related complications is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biopharmaceuticals, and more specifically to application of a polygonatum odoratum extract in preparing a medicine for improving type 2 diabetes. Background Art

[0002] Diabetes mellitus (DM) is one of the most common metabolic diseases, mainly including type 1 diabetes, type 2 diabetes mellitus (T2DM) and gestational diabetes. Since the 21st century, the incidence of diabetes has continued to rise, and the incidence population is becoming younger. The persistent hyperglycemia state of T2DM can cause a variety of complications, including cardiovascular disease, diabetic nephropathy, retinopathy, peripheral neuropathy and osteoporosis. Therefore, the prevention and treatment of T2DM is a major research area in clinical science.

[0003] Currently, the main drugs used in clinical prevention and treatment are metformin, glibenclamide, acarbose and miglitol, however, they may cause different side effects such as nausea, vomiting, flatulence, diarrhea and hypoglycemia. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides the use of polygonatum odoratum extract in preparing a medicine for improving type 2 diabetes.

[0005] Furthermore, the polygonatum odoratum extract improves type 2 diabetes through the synergistic effects of intestinal microbiota and serum metabolism.

[0006] Furthermore, the polygonatum odoratum extract is used to improve insulin sensitivity and regulate glucose and lipid metabolism.

[0007] Furthermore, the Polygonatum odoratum extract is used to regulate the relative abundance of Alistipes, Odoribacter, Rikenella, Blautia and Ruminococcus.

[0008] Furthermore, the polygonatum odoratum extract is used to restore abnormal metabolites in serum.

[0009] Furthermore, the Polygonatum odoratum extract is the only active ingredient.

[0010] Furthermore, the polygonatum odoratum extract is a polygonatum odoratum methanol extract.

[0011] Furthermore, the polygonatum odoratum extract comprises: flavonoid compounds, isoflavone compounds, pregnenolone lipid compounds, benzene and substituted derivatives.

[0012] The results of the present invention show that Polygonatum odoratum extract (PO) can significantly improve the blood sugar, body weight, blood lipids and inflammation levels of mice, and PO can also improve the pathological changes of liver, intestines and kidneys. In addition, PO helps to correct the disorder of intestinal microecology, and by restoring the relative abundance of key bacteria such as Alistipes, Odoribacter, Rikenella, Blautia and Ruminococcus, regulates the level of SCFAs, and contributes to the healthy balance of the intestinal microecological system. PO can restore the levels of metabolites such as sphingolipids and glycerophospholipids to normal, improve the insulin sensitivity of diabetic mice and regulate glucose and lipid metabolism through pentose phosphate, glycerolipid metabolism, mTOR signaling pathway and other pathways, and also show certain anti-inflammatory effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] The following are drawings of exemplary embodiments of the present invention, and the same or similar reference numerals are used in the drawings to represent the same or similar elements. In the drawings:

[0014] Figure 1 The weight, FBG, AUG, OGTT and organ index changes of mice in each experimental group; weight change (A), FBG (B), OGTT AUC (C), OGTT (D), liver coefficient (E), pancreas coefficient (F), kidney coefficient (G), spleen coefficient (H); #p<0.05vs normal control, ##p<0.01vs normal control, *p<0.05vs model, **p<0.01vs model;

[0015] Figure 2 The changes of blood lipid and inflammation levels in mice in each experimental group; HDL-C (A), LDL-C (B), TG (C), TC (D), IL-1β (E), IL-6 (F), IL-10 (G), TNF-α (H); # p<0.05vs. normal control, ## p<0.01 vs. normal control, *p<0.05 vs. model, **p<0.01 vs. model, + p<0.05vs PO-L, ++ p<0.01vs PO-L;

[0016] Figure 3 Pathological changes and scores of mouse tissues in each experimental group; colon pathology score (A), kidney pathology score (B), liver pathology score (C), colon tissue pathology change diagram (D), kidney tissue pathology change diagram (E), liver tissue pathology change diagram (F); ## p<0.01 vs normal control, **p<0.01 vs model;

[0017] Figure 4Alpha and Beta diversity analysis of the intestinal microbiota of mice in each experimental group; Chao1 (A), Shannon (B), Observed species (C), Goods coverage (D), PCoA Analysis (E), NMDSAnalysis (F);

[0018] Figure 5 The changes in the phylum and genus levels of the intestinal flora of mice in each experimental group; the distribution ratio of intestinal flora at the phylum level (A), the relative abundance of Protrobacteria, Actinobacteriota, and Verrucomicrobiotada (BD), the distribution ratio of intestinal flora at the genus level (E), and the relative abundance of Alistipes, Odoribacter, Rikenella, and Alcaligenes (FI); # p<0.05vs normal control, ## p<0.01 vs normal control, *p<0.05 vs model, **p<0.01 vs model;

[0019] Figure 6 AD shows the changes in the concentration of SCFAs in mice in each experimental group, including acetate (A), propionate (B), isovaleric acid (C), and butyric acid (D);

[0020] Figure 6 E is the differential analysis of LEfSe of intestinal flora;

[0021] Figure 6 F is the correlation analysis, where blue and red represent negative correlation and positive correlation, respectively;

[0022] Figure 6 G is the evolutionary branch diagram;

[0023] Figure 7 For the prediction of intestinal flora function; difference analysis between normal control and model (A), difference analysis between model and PO-L (B), difference analysis between PO-L and PO-H (C), difference analysis between model and PO-H (D);

[0024] Figure 8 Effects of PO on serum metabolic profiles and metabolites of T2DM mice; PCA (A), OPLS-DA (BC, EF), Permutation (D), model vs normal control (G), model vs positive control group (H), model vs PO-L (I), model vs PO-H (J);

[0025] Fig. 9 To analyze the characteristic differential metabolites affected by PO;

[0026] Fig.10 The present invention predicts the serum metabolism of PO based on KEGG pathway analysis; normal control vs model (A), model vs positive control group (B), model vs PO-L (C), model vs PO-H (D);

[0027] Fig.11 This is the correlation analysis between intestinal flora and serum metabolites of the present invention. DETAILED DESCRIPTION

[0028] The present invention is further described below with reference to specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0029] 1. Experimental sample: Polygonatum odoratum methanol extract (PO)

[0030] 1.1 Preparation of PO

[0031] Polygonatum odoratum was provided by Ji'an Tianhe Ginseng and Deer Antler Products Co., Ltd. (222894S-2019).

[0032] After crushing, the extract was filtered and extracted three times with methanol at room temperature, and the resultant was concentrated to obtain the methanol extract of Polygonatum odoratum, named PO. PO was concentrated to dryness in a vacuum to provide a sample for biological experimental detection.

[0033] 1.2 Analysis of PO components

[0034] The sample was centrifuged and the supernatant was filtered. The filtrate was subjected to ACQUITY T3 was subjected to UHPLC-QE-MS analysis.

[0035] Chromatographic parameters:

[0036] Chromatographic column (2.1×150mm, 1.8μm);

[0037] Mobile phase: negative ion: 5 mM ammonium formate aqueous solution (A) and acetonitrile (B), positive ion: 0.1% formic acid aqueous solution (C) and 0.1% formic acid acetonitrile solution (D);

[0038] Gradient elution: 0-1min, 2% B / D; 1-9min, 2%-50% B / D; 9-12min, 50%-98% B / D; 12-13.5min, 98% B / D; 13.5-14min, 98%-2% B / D; 14-20min, 2% D positive mode (14-17min, 2% B negative mode) gradient was performed under the conditions.

[0039] Mass spectrometry analysis parameters: electrospray ionization (ESI) source, positive and negative ion ionization modes, positive ion spray voltage 3.50 kV, negative ion spray voltage 2.50 kV, sheath gas 30 arb, auxiliary gas 10 arb, capillary temperature 325 °C, mass spectrometry scanning range 100-1000, resolution 60000.

[0040] 2. Experimental Methods

[0041] 2.1 Animal Experiment Design

[0042] C57BKS-db (8 weeks old, 45±2g) and C57BKS (8 weeks old, 25±2g) mice were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. The mice were placed under ambient temperature (18-24°C) and artificial LED light cycle (16h light, 8h dark) to maintain normal diet and free drinking water. After fasting for 12h, blood was collected from the tail vein, and blood glucose was tested weekly with a blood glucose meter. Mice with random blood glucose >11.1mmol / L were in a hyperglycemic state, which met the T2DM mouse modeling criteria.

[0043] C57BKS mice served as the normal control group and were given normal saline by gavage.

[0044] The T2DM mice were randomly divided into 4 groups:

[0045] The diabetic model group (Model) was given normal saline by gavage;

[0046] The positive control (Metformin) group was given metformin hydrochloride (DMBG, 200 mg / kg) by gavage;

[0047] The Polygonatum odoratum low concentration (PO-L) treatment group was given intragastric administration of Polygonatum odoratum extract (PO, 400 mg / kg);

[0048] The Polygonatum odoratum high concentration (PO-H) treatment group was given Polygonatum odoratum extract (PO, 800 mg / kg) by gavage.

[0049] Each group of mice (N=5) was gavaged at the same time during the experiment, once a week. Fresh feces were collected during the treatment and immediately stored at -80°C for subsequent analysis. After 12 hours of food deprivation, blood was collected from the tail to measure FBG, and then glucose (2 mg / kg) was gavaged for OGTT test. After 8 weeks of continuous intervention, blood was collected from the eyeball vein and the mice were killed by cervical dislocation.

[0050] 2.2 Body weight, fasting blood glucose (FBG), oral glucose tolerance test (OGTT)

[0051] During the experiment, body weight was recorded weekly. After weekly administration, mice were fasted but not watered for more than 12 hours, and blood samples were collected from the tail of mice. FBG was measured using a blood glucose monitor and blood glucose test strips, which was the baseline blood glucose value at 0 min. OGTT test was then performed by intragastric administration of glucose solution at a dose of 2 mg / kg. Blood glucose values ​​of the tail vein blood of mice were measured at 30, 60, and 120 minutes after intragastric administration, and the area under the blood glucose concentration curve (AUC) was calculated.

[0052] 2.3 Liver index

[0053] After 8 weeks of drug intervention, the mice were killed, and their weights were recorded before killing. After killing, the liver, kidney, pancreas, and spleen tissues of the mice were collected by dissection, washed with saline, and the water was absorbed with filter paper, and then weighed separately, which was the organ mass. The corresponding organ index was calculated as follows: Organ index = (organ weight / mouse weight) × 100.

[0054] 2.4 Enzyme-linked immunosorbent assay (ELISA)

[0055] After 8 weeks of drug intervention, blood samples were collected from the mouse ocular vein using EDTA vacuum blood collection tubes, left to stand for 2 hours, centrifuged at 3000×g for 10 minutes at 4°C, and the supernatant was aspirated to separate the plasma. According to the manufacturer's instructions, commercial kits were used to detect the levels of interleukin-1β (IL-1β, PROTP10749), interleukin-10 (IL-10, EK0417), interleukin-6 (IL-6, EK0411), and tumor necrosis factor-α (TNF-α, EK0527) inflammatory factors in mouse plasma. After the blood was allowed to stand, it was heated in a 37°C water bath for 30 min and centrifuged at 10,000×g for 5 min to separate the serum. The levels of total cholesterol (TC, CH01, 20210622), triglycerides (TG, TG01, 20210618), high-density lipoprotein cholesterol (HDL-C, HL01, 20210522), and low-density lipoprotein cholesterol (LDL-C, LDL01, 20210428) in the serum were detected according to the instructions of the kit.

[0056] 2.5 Case observation

[0057] After killing the mice, the processed liver, kidney and 0.5 cm distal colon tissues were fixed in 4% paraformaldehyde for 48 h and then removed. They were dehydrated, embedded, sliced ​​and stained with hematoxylin-eosin using a gradient of low to high concentrations of ethanol. After sealing, the tissue morphology was observed under a microscope and the tissue pathology score was performed.

[0058] 2.6 Analysis of short-chain fatty acids (SCFAs)

[0059] Gas chromatography (GC) was used to determine the SCFA in fecal samples, including acetic acid, propionic acid, butyric acid, and isovaleric acid. 50 mg of feces was taken, mixed with buffer at a ratio of 1:10, dissolved, and homogenized. Then centrifuged at 10,000 r / min for 5 minutes at 4°C. Filtered through 0.45 mm sterile filter paper, stored in a centrifuge tube, and then SCFAs were quantitatively analyzed using gas chromatography (Shimadzu DB-FFAP, Japan, Agilent Technologies, USA).

[0060] 2.7 16S rRNA gene sequencing

[0061] Shanghai Ouyi Biomedical Technology Co., Ltd. performed 16S rRNA sequencing and amplified the V3-V4 region of the samples (343F:'TACGGRAGGCAGCAG'; 798R:'AGGGTATCTAATCCT'). The original double-end sequences were decontaminated using Trimmomatic software, and the sequences were classified into multiple OTUs based on sequence similarity using Vsearch software. The representative sequences were then compared with the Silva (version138) database using the QIIME software package. Alpha and beta diversity determinations (shannon, good_coverage, observed_species, PCoA, and NMDS) were also performed in QIIME. LEfSe analysis and linear discriminant analysis (LDA) were used to screen the differential flora between the groups and identify potential biomarkers. The Spearman algorithm was used for correlation analysis to present the correlation heat map between bacterial taxa and T2DM-related environmental factors. The identified intestinal microbiota were functionally predicted according to the KEGG database, and STAMP was used to analyze the differences in microbial functional prediction between the groups.

[0062] 2.8 LC / MS non-targeted metabolomics analysis

[0063] Take 70 μL of sample, add 20 μL of internal standard (L-2-chlorophenylalanine, 0.06 mg / mL methanol), vortex, then add 280 μL of protein precipitant methanol-acetonitrile (V:V=2:1), vortex for 1 min. Ultrasonic extraction for 10 min and stand at -20 ° C for 30 min. Centrifuge for 10 min (13000 rpm, 4 ° C), take 280 μL of supernatant, evaporate and then re-dissolve with 300 μL of methanol-water (V:V=1:4), stand and centrifuge for 10 min (13000 rpm, 4 ° C), take 150 μL of supernatant, filter, transfer to injection vial, and perform LC-MS analysis. Quality control samples (QC) are prepared by mixing equal amounts of extracts from all samples to maintain the stability of the analysis process, ensure the quality and credibility of the data, and thus improve the repeatability and comparability of the experiment. Metabolomics analysis was performed using an ACQUITY UPLC I-Class plus ultra-high performance liquid phase tandem QE high-resolution mass spectrometer. The chromatographic column was ACQUITY UPLC HSS T3 (100mm×2.1mm, 1.8um), 45°C, flow rate 0.35mL / min, and injection volume 2μL. The mobile phase contained A-water (containing 0.1% formic acid) and B-acetonitrile (containing 0.1% formic acid). B was eluted with a gradient of: 0.01-2min, 5%; 4min 30%; 8min 50%; 10min 80%; 14-15min 100%; 15.1-16 5%. Electrospray ionization (ESI) was used to collect the mass spectrometry signals of the samples in positive and negative ion scanning modes respectively. The mass spectrometry data acquisition range was 100-1200Da. The settings of ESI are: Sheath Gas Flow Rate (Arb) 40; Aux Gas Flow Rate (Arb) 10; Capillary Temperature (°C) 320.

[0064] The raw data were subjected to baseline filtering, peak identification, integration, retention time correction, peak alignment and normalization by the metabolomics processing software Progenesis QI v2.3 software (NonlinearDynamics, Newcastle, UK), and compared with the human metabolome database (HMDB), Lipidmaps (v2.3) and METLIN databases and self-built libraries. The ion peaks with missing values>50% were deleted from the extracted data, and subsequent analysis was performed after screening. Principal component analysis (PCA) and orthogonal partial least squares analysis (OPLS-DA) were used to determine the differential metabolites between groups. The screening criteria of the present invention were VIP>1, T test p-value<0.05. On this basis, metabolites that simultaneously met VIP>1 and p<0.05 were screened as differential metabolites, and pathway enrichment analysis was performed using their KEGG IDs.

[0065] 2.9 Statistical methods

[0066] All data were expressed as SD ± mean, and the data were analyzed using SPASS22.0 and GraphPad Prism9.0 programs. One-way ANOVA was used for comparison among multiple groups, and the Student-Newman-Keuls method was used for multiple comparisons of sample means. P values ​​< 0.05 or 0.01 were considered statistically significant.

[0067] 3. Experimental results

[0068] 3.1 Identification of the chemical composition of PO

[0069] The present invention uses UHPLC-QE-MS technology to conduct an in-depth study of PO components, and combines the data of the Traditional Chinese Medicine System Pharmacology (TCMSP) and the analytical platform database to screen for bioactive compounds using the standards of oral bioavailability (OB%) and drug-likeness (DL) content (OB%>30 and DL>0.18). Table 1 provides detailed information such as the mass-to-charge ratio and type of the identified active compounds.

[0070] Table 1 Chemical composition identification of PO

[0071]

[0072]

[0073] 3.2 Body weight, FBG, OGTT, and organ index

[0074] The experimental results are as follows Figure 1As shown. In the early stage of intervention, except for the normal control group, there was no significant difference in the initial body weight among the four groups. After drug treatment intervention, the body weight gradually decreased. After 8 weeks of intervention, compared with the model group, the present invention found that the body weight of mice in the positive control group decreased significantly (P<0.05), and the body weight of mice in the PO-H group decreased significantly (P<0.01), and the differences were statistically significant ( Figure 1 A).

[0075] Compared with the normal control group, the fasting blood glucose (FBG) and AUC levels in the model group were significantly increased (P<0.01); compared with the model group, the positive control group and the Polygonatum odoratum treatment group significantly reduced the FBG and AUC levels and improved glucose tolerance. Figure 1 B, C, The OGTT blood glucose level of the model group at each time point was significantly higher than that of the normal control group (P<0.01). Compared with the model group, the OGTT blood glucose level of the positive control group and the Polygonatum odoratum treatment group at 30 minutes was significantly reduced (P<0.01); especially the OGTT blood glucose level of the PO-H group mice at 60 minutes, 90 minutes, and 120 minutes was significantly reduced (P<0.05) ( Figure 1 D).

[0076] Compared with the normal control group, the liver, kidney, pancreas and spleen indexes of the model group mice were significantly different (P<0.01) ( Figure 1 EH). Compared with the model group, the liver and kidney indexes of the mice in the PO-L group were significantly different (P<0.01), the liver and kidney indexes of the mice in the positive control group and the PO-H group were significantly decreased (P<0.01), and the pancreas and spleen indexes were significantly increased (P<0.01).

[0077] Therefore, PO can reduce the body weight and hyperglycemia symptoms of mice and its effects on organ indexes of T2DM mice.

[0078] 3.3 Blood lipids and inflammatory factors

[0079] The experimental results are as follows Figure 2 shown. Figure 2 Compared with the normal control group mice, the blood TG of the AD model group mice was at a high level (p<0.01), indicating that they may suffer from hyperlipidemia. Compared with the model group mice, the HDL-C in the positive control group and the PO-H group was significantly increased (p<0.01), and the levels of TG, TC, and LDL-C were significantly decreased (p<0.01). After oral gavage with PO-L, the TG level decreased (p<0.05), and the TC level decreased significantly (p<0.01). The therapeutic effects of low-concentration and high-concentration Polygonatum odoratum were compared, and it was found that the therapeutic effect of PO-H on the blood lipids of diabetic mice was better than PO-L, among which the therapeutic effect on the levels of HDL-C, TG, and TC was significantly better than PO-L (p<0.01). The detection of plasma inflammatory cytokines found that ( Figure 2 EH), compared with the model group, the levels of pro-inflammatory factors IL-1β and TNF-α in the PO-L group mice were significantly reduced (P<0.05), and the levels of IL-6, IL-1β and TNF-α in the positive control group and the PO-H group were significantly reduced (P<0.01). The anti-inflammatory factor IL-10 was significantly increased in the Polygonatum odoratum treatment group (P<0.05), especially the IL-10 level of the PO-H group mice was significantly increased (P<0.01), which was statistically significant. A large number of studies have shown that T2DM causes a decrease in the HDL-C level in the blood of mice, while the levels of TC, TG and LDL-C increase, which is consistent with the research results of the present invention.

[0080] Therefore, PO can improve the levels of hyperlipidemia and inflammation in T2DM mice.

[0081] 3.4HE pathological sections

[0082] The experimental results are as follows Figure 3 As shown in the figure, compared with the normal control group, the model group mice had severe organ damage (p<0.01), thickening of colonic crypts accompanied by abscesses, disappearance of goblet cells, local intestinal epithelial shedding, and a large number of inflammatory cells. The glomerular mesangium expanded, glomerular atrophy, renal tubular epithelial vacuoles degenerated, and a large number of inflammatory cells infiltrated. The hepatocytes were swollen, and lipid droplets and inflammatory cells were obvious ( Figure 3 DF). After treatment with metformin and Polygonatum odoratum, Figure 3 AC, these characteristic pathological changes in organs of type 2 diabetic mice were significantly improved (p<0.01).

[0083] 3.5 16S rRNA gene sequencing

[0084] 3.5.1α / β analysis

[0085] α diversity analysis reflects the diversity of species, among which Chao1 index is proportional to species richness. Shannon index, Good_coverage index and Observed_species index reflect species diversity. The larger the Shannon value, the higher the species richness and uniformity. The higher the Observed species index, the higher the species richness. β analysis includes principal coordinate analysis (PCoA) and non-metric multidimensional scaling analysis (NMDS). The present invention found that, if Figure 4As shown in the figure, compared with the mice in the normal control group, the intestinal flora richness of the mice in the model group was reduced, and the flora richness of the mice in the Polygonatum odoratum treatment group was closer to that of the normal control group. Compared with the mice in the normal control group, the Shannon index and the observed species index of the mice in the model group were significantly reduced. Compared with the model group, the Shannon index and the observed species index of the positive control group, PO-L and PO-H groups increased. T2DM reduces the richness and diversity of the intestinal flora of mice. The Good_coverage index reflects the depth of sample sequencing. The Good_coverage index of the five groups of mice was greater than 97%, indicating that there was sufficient detection depth. In addition, in order to compare the differences in the composition of the intestinal microbiota between the groups, PCoA and NMDS analysis intuitively reflected the inter-group differences and intra-group similarities of the samples. The results showed that the composition structure of the intestinal flora of mice was significantly different between the groups (p<0.001). The model group and the normal control group showed completely different distributions in the data space, while the distribution between the PO-H group and the positive control group was very similar.

[0086] 3.5.2 Phylum analysis

[0087] According to the sequencing results, the present invention annotated the intestinal microbial community composition of all samples. At the phylum level, the top 20 dominant bacterial communities with the highest relative abundance were selected for analysis, such as Figure 5 As shown. Among them, Bacteroidota, Firmicutes, Protrobacteria and Actinobacteriota account for a large proportion ( Figure 5 A) After drug gavage treatment, the relative abundance of intestinal flora in T2DM mice changed at the phylum level. Figure 5 BD, compared with the normal control group, the relative abundance of Protrobacteria and Actinobacteriota in the model group mice increased, and the relative abundance of Verrucomicrobiotada decreased, among which the relative abundance of Actinobacteriota increased significantly (p<0.01). After intragastric administration of metformin or Polygonatum odoratum, the relative abundance of Protrobacteria and Actinobacteriota in the positive control group, PO-L, and PO-H groups decreased, and the relative abundance of Verrucomicrobiotada increased, among which the relative abundance of Actinobacteriota in the PO-L group decreased (p<0.05), which was statistically significant, and the relative abundance of Actinobacteriota in the PO-H group decreased significantly (p<0.01). At the genus level ( Figure 5EI), the abundance of Odoribacter changed significantly, and metformin or Polygonatum odoratum treatment could effectively increase the abundance of Odoribacter (p<0.01). Compared with the model group, the abundance of Rikenella increased in the PO-L group (p<0.05). In addition, after PO-L treatment, the abundance of Alistipes increased from 3.94% to 5.18%, and the abundance of Alcaligenes decreased from 4.54% to 1.35%.

[0088] 3.5.3LEfSe analysis

[0089] LEfSe analysis was used to determine the significantly different bacterial species between groups. When the linear discriminant analysis (LDA) value was >3, the present invention screened out 61 different genera ( Figure 6 E, G). Proteobacteria, Bacteroides, and Providencia were the most abundant taxa in the model group. Firmicutes, Clostridia, Lachnospiraceae, Enterobacteriaceae, and Escherichia were the most abundant taxa in the PO treatment group. Campilobacterota, Helicobacter, Odoribacter, Oscillospiraceae, and Ruminococcaceae were the most abundant taxa in the positive control group.

[0090] 3.5.4SCFAs

[0091] The present invention has detected the content of short-chain fatty acids in mouse feces. Figure 6 The concentrations of acetate, propionate, butyrate and isovaleric acid in the AD model group were significantly lower than those in the normal control group. After PO-L administration, the concentrations of SCFAs in the mice increased, especially propionate and butyrate (P<0.01). The concentrations of acetate, propionate, butyrate and isovaleric acid in the PO-H group were significantly increased (P<0.01).

[0092] 3.5.5 Correlation analysis

[0093] like Figure 6 F, Correlation analysis between T2DM indexes and intestinal flora abundance showed that intestinal flora was closely related to environmental factors. Corynebacterium and Alcaligenes were positively correlated with liver coefficient, HDL-C, and LDL-C (p<0.05), and negatively correlated with butyrate (p<0.05). In addition, Ruminococcus and Erysipelatoclostridium were negatively correlated with isobutyrate (p<0.05).

[0094] 3.5.6 Function Prediction

[0095] PICRUST2 analysis can predict the potential "function" of the microbiota based on gene sequences. Figure 7 AD is the function that the corresponding intestinal microbiota may predict in the KEGG database. The results showed that the normal control group and the model group had significant differences in Betalain and steroid biosynthesis, plant circadian rhythm, signaling pathway and colorectal cancer (p<0.01). After oral administration of Polygonatum odoratum, there were significant improvements in transporters, pentose phosphate pathway, porphyrin and chlorophyll metabolism, amino sugar and nucleotide sugar metabolism, fructose and mannose metabolism, galactose metabolism, etc. (p<0.01). The therapeutic effects of the PO-L and PO-H groups were significantly different mainly in the p53 signaling pathway (p<0.01).

[0096] 3.6 Serum metabolism

[0097] Intestinal microbiota plays a vital role in nutrient digestion and absorption, thus affecting blood metabolism. The present invention uses gas chromatography-mass spectrometry to detect mouse serum metabolites in positive and negative ion modes. First, PCA analysis is performed on the data of the five groups, such as Figure 8 A, the QC points of the quality control samples are closely clustered, indicating that the entire experimental process is repeatable and the data are normal. In order to maximize the difference in metabolic profiles, the present invention performed partial least squares discriminant analysis (OPLS-DA). The present invention evaluated the model fitness (R2) and predictive ability (Q2). The results clearly showed the differences in metabolite composition between the normal control and the model, the model and the positive control group, the model and PO-L, and the model and PO-H ( Figure 8 BC, EF). At the same time, the present invention carried out 200 iterations of permutation test on the above model, and the results showed that the slopes of R2Y and Q2Y systems were close to zero, indicating that the model was not overfitted and was reliable ( Figure 8 D).

[0098] On the basis of establishing the OPLS-DA model, the present invention further uses VIP and P-value to screen differential metabolites. Metabolites that simultaneously meet VIP>1 and P<0.05 are considered to be potential differential metabolites. The present invention uses Volcano plot to visualize P value and VIP value ( Figure 8GH), the results showed that there were 243 differential metabolites in the comparison between the normal control group and the model group. Among them, 106 metabolites were up-regulated and 137 metabolites were down-regulated; in the comparison between the model group and the positive control group, there were 191 differential metabolites. Among them, 103 metabolites were up-regulated and 88 metabolites were down-regulated; in the comparison between the model group and the PO-L group, there were 191 differential metabolites. Among them, 109 metabolites were up-regulated and 82 metabolites were down-regulated; in the comparison between the model group and the PO-H group, there were 117 differential metabolites. Among them, 79 metabolites were up-regulated and 38 metabolites were down-regulated.

[0099] Fig. 9 To analyze the characteristic differential metabolites affected by PO;

[0100] In the cluster analysis heat map, oxidanesulfonic acid1 is the abbreviation of the metabolite (5-{8-[1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-hydroxypropyl]-3,5,7-trihydroxy-3,4-dihydro-2H-1-benzopyran-2-yl}-2-hydroxyphenyl)oxidanesulfonic acid, and oxidanesulfonic acid2 is the abbreviation of the metabolite {5-[3-(2,4-dihydroxyphenyl)-3-[2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-1-benzopyran-8-yl]-2-hydroxypropyl]-2-hydroxyphenyl}oxidanesulfonic acid. Colors from blue to red indicate the expression abundance of metabolites from low to high (A) {5-[3-(2,4-dihydroxyphenyl)-3-[2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-1-benzopyran-8-yl]-2-hydroxypropyl]-2-hydroxyphenyl}oxidanesulfonic acid (B) GM4 (d18:1 / 20:0) (C) PI (18:0 / 20:4 (5Z,8Z,11Z,14Z)) (D) Correlation analysis of PO-L and PO-H metabolites (E).

[0101] Cluster analysis heat map showing the differences in metabolite distribution among groups ( Fig. 9 A). The present invention selects the top-50 metabolites with significant differences. Compared with the normal control group, PE-NMe2(15:0 / 22:4(7Z,10Z,13Z,16Z)), {5-[3-(2,4-dihydroxyphenyl)-3-[2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-1-benzopyran-8-yl]-2-hydroxypropyl]-2-hydroxyphenyl}oxidanesulfonic acid( Fig. 9 B) and other reductions, PI (18:0 / 20:4 (5Z, 8Z, 11Z, 14Z)) ( Fig. 9 D)、GM4(d18:1 / 20:0)( Fig. 9 C), LysoPC (0:0 / 18:0), PS (O-20:0 / 20:3 (8Z, 11Z, 14Z)), PC (14:1 (9Z) / 20:0), etc. Compared with the model group, these changes were reversed in the PO-L group, PO-H group and positive control group. Fig. 9 E. The results of metabolite correlation analysis between the PO-L group and the PO-H group showed that some metabolites of PO-L and PO-H were correlated, indicating that the effects of PO-L and PO-H on serum metabolites were similar. Most of these metabolites are lipid molecules that play a very important role in small intestinal function, which indicates that the methanol extract of Polygonatum odoratum restored the metabolites in serum that were disturbed by T2DM.

[0102] To further explore the metabolic pathways related to metabolites, all differential metabolites in different comparison groups were matched to the KEGG database to obtain the pathway information involved in the metabolites. Enrichment analysis was performed on the annotated results to obtain pathways with more differential metabolites enrichment ( Fig.10 AD), the y-axis is the name of the metabolic pathway, and the x-axis is Rich factor = the number of significantly different metabolites / the total number of metabolites in the pathway). The larger the Rich factor, the greater the degree of enrichment. The node color decreases from green to red, and the p-value scale decreases, and the size of the node corresponds to the number of metabolites enriched in the pathway. Compared with the Polygonatum odoratum treatment group, the specific pathways enriched in the model group are glycerolipid metabolism, pentose phosphate pathway, glycolysis / gluconeogenesis, and mTOR signaling pathway. The specific pathways enriched in the Polygonatum odoratum treatment group and the positive control group include regulating fat decomposition of adipocytes, arginine and proline metabolism, and D-amino acid metabolism. These pathways reflect the positive role of Polygonatum odoratum methanol extract in improving serum metabolic disorders.

[0103] 3.7 Correlation between gut microbiota and serum metabolites

[0104] In order to study the relationship between intestinal flora and serum metabolites, the present invention performed Spearman's correlation analysis on intestinal flora and serum metabolites ( Fig.11 A, B).

[0105] Correlation heatmap at genus level (oxidanesulfonic acid1 is the abbreviation of metabolite (5-{8-[1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-hydroxypropyl]-3,5,7}-trihydroxy-3,4-dihydro-2H-1-benzopyran-2-yl}-2-hydroxyphenyl)oxidanesulfonic acid) (A) Correlation heatmap at phylum level (B) (blue and red represent negative and positive correlation, respectively. *p<0.05; **p<0.01).

[0106] At the phylum level, the present study found that Verrucomicrobiota was negatively correlated with PE (18:0 / 17:0), PS (O-18:0 / 20:2 (11Z, 14Z)) and 1-O-(2-methoxy-4Z-hexadecenyl)-sn-glycero-3-phosphocholine (p<0.05). The relative abundance of Actinobacteriota and Proteobacteria decreased in the Polygonatum odoratum treatment group and the positive control group, and was positively correlated with PC (18:3 (6Z, 9Z, 12Z) / 20:3 (5Z, 8Z, 11Z)) (p<0.05). Actinobacteriota was also positively correlated with PS (O-18:0 / 20:2 (11Z, 14Z) (p<0.05)

[0107] At the genus level, compared with the model group, the significantly decreased microbiota in the intestinal flora of mice treated with methanol extract of Polygonatum odoratum showed significant negative correlation with lipid metabolites. Rikenella and Alistipes were significantly negatively correlated with 3-amino-2-naphthoic acid (p<0.01). Odoribacter was positively correlated with (5-{8-[1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-hydroxypropyl]-3,5,7-trihydrox y-3,4-dihyd ro-2H-1-benzopyra n-2-yl}-2-hydroxyphenyl)oxidane sulfonic acid and positively correlated with Lyso PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)), PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z) / 0:0), LysoPC(18:2(9Z,12Z)), GM4(d18:1 / 16:0), PC(16:0 / 0:0), PC(16:0 / 0:0)[rac] and LysoPC(0:0 / 16:0) were negatively correlated (p<0.05). The intestinal microbiota enriched in the model group was significantly positively correlated with lipid metabolites and significantly negatively correlated with flavonoids.

[0108] The present invention found that the methanol extract of Polygonatum odoratum showed a wide range of physiological effects in the treatment of T2DM mice. It helps to reduce the weight of T2DM mice, improve blood sugar control, and has a protective effect on multiple organs. It helps to alleviate the degree of pathological changes in organs such as the intestines, liver, and kidneys, and provides multi-level health protection. It also plays a positive role in changing the composition of the intestinal flora of T2DM mice. It helps to correct the disorder of intestinal microecology, and by regulating the relative abundance of key bacteria such as Alistipes, Odoribacter, Rikenella, Blautia, and Ruminococcus, it increases the relative abundance of Alistipes, Odoribacter, Rikenella, and Blautia, and reduces the relative abundance of Ruminococcus, which helps to restore the healthy balance of the intestine. This intervention is also a potential mechanism for improving T2DM symptoms by regulating the level of SCFAs. In addition, the methanol extract of Polygonatum odoratum can also reverse the abnormal metabolites such as sphingolipids and glycerophospholipids, improve the insulin sensitivity of T2DM and regulate glucose and lipid metabolism through pentose phosphate, glycerolipid metabolism, mTOR signaling pathway and other pathways, reduce the production of cytokines and the release of inflammatory mediators, and reduce the degree of chronic inflammation. In short, the methanol extract of Polygonatum odoratum can intervene in the development of T2DM at multiple biological levels, thereby improving the quality of life of patients and reducing the risk of related complications.

[0109] It is to be understood that the present invention is described by some embodiments, and it is known to those skilled in the art that various changes or equivalent substitutions may be made to these features and embodiments without departing from the spirit and scope of the present invention. In addition, under the teachings of the present invention, these features and embodiments may be modified to adapt to specific circumstances and materials without departing from the spirit and scope of the present invention. Therefore, the present invention is not limited by the specific embodiments disclosed herein, and all embodiments falling within the scope of the claims of this application are within the scope of protection of the present invention.

Claims

1. The application of Polygonatum odoratum extract in the preparation of drugs for improving type 2 diabetes.

2. The use of the polygonatum odoratum extract according to claim 1 in the preparation of a drug for improving type 2 diabetes, characterized in that: The polygonatum odoratum extract improves type 2 diabetes via the synergistic effects of intestinal microbiota and serum metabolism.

3. The use of the polygonatum odoratum extract according to claim 1 in the preparation of a medicament for improving type 2 diabetes, characterized in that: The polygonatum odoratum extract is used for improving insulin sensitivity and regulating sugar and lipid metabolism.

4. The use of the polygonatum odoratum extract according to claim 1 in the preparation of a medicament for improving type 2 diabetes, characterized in that: The polygonatum odoratum extract is used to regulate the relative abundance of Alistipes, Odoribacter, Rikenella, Blautia and Ruminococcus.

5. Use of the polygonatum odoratum extract according to claim 1 in preparing a medicament for improving type 2 diabetes, characterized in that: The polygonatum odoratum extract is used to restore abnormal metabolites in serum.

6. Use of the polygonatum odoratum extract according to claim 1 in preparing a drug for improving type 2 diabetes, characterized in that: The polygonatum odoratum extract is the only active ingredient.

7. Use of the polygonatum odoratum extract according to claim 1 in preparing a medicament for improving type 2 diabetes, characterized in that: The polygonatum odoratum extract is a methanol extract of polygonatum odoratum.

8. Use of the polygonatum odoratum extract according to claim 1 in preparing a drug for improving type 2 diabetes, characterized in that: The polygonatum odoratum extract comprises: flavonoid compounds, isoflavone compounds, pregnenolone lipid compounds, benzene and substituted derivatives.

Citation Information

Patent Citations

  • Application of polygonatum odoratum extract in preparation of medicine for treating inflammatory bowel disease

    CN115040606A